FDA 2026 Guidance on Voluntary Patient Preference Information
FDA’s 2026 PPI guidance encourages voluntary collection of patient preference information across the total product life cycle. Devices with direct patient interfaces, subjective outcomes, or high risks benefit most. PPI supports premarket submissions, labeling, and post-market evaluation. Guidance aligns with EU MDR/IVDR PMCF/PMPF principles, helping assess patient risk tolerance and benefit-risk trade-offs. Manufacturers should collect scientifically valid PPI to inform regulatory decision-making and enhance patient-centered device development.
The FDA 2026 guidance on voluntary Patient Preference Information (PPI) encourages device manufacturers to integrate patient perspectives across the total product life cycle. This update expands the 2016 guidance, highlighting PPI’s role from device design to post-market surveillance. Incorporating patient feedback supports regulatory decision-making, especially for devices with direct patient interfaces, subjective outcomes, or high-risk profiles. Understanding this guidance is essential for U.S. medical device submissions and aligns with global patient-centric trends, including EU MDR/IVDR post-market follow-up practices.
Key Updates in FDA PPI Guidance 2026
Encourages PPI collection throughout the total product life cycle (TPLC), not just premarket.
Highlights types of devices where PPI is most impactful: direct patient interface, subjective outcomes, high-risk, and unmet need devices.
Voluntary submission, but guidance outlines best practices for study design and analysis to ensure regulatory relevance.
Aligns conceptually with EU MDR/IVDR post-market clinical/performance follow-up (PMCF/PMPF), helping evaluate patient risk tolerance and benefit-risk trade-offs.
Impact on Regulatory Submissions
PPI can strengthen the scientific evidence supporting premarket submissions, labeling decisions, and post-market surveillance strategies.
FDA may consider well-collected PPI when evaluating benefit-risk profiles, especially for subjective or high-risk devices.
Encourages proactive patient engagement strategies to improve device adoption, compliance, and market success.
How to Comply and Leverage PPI
Identify critical device attributes that influence patient preferences early in design.
Collect PPI using scientifically valid methods (surveys, discrete choice experiments, or focus groups).
Integrate findings in regulatory submissions, clinical trial design, and post-market evaluations.
Document methods and rationale to ensure FDA reviewers understand the relevance of PPI evidence.
Internal links
- Learn more about FDA US Medical Device Registration
External links
MarketFDA US Medical Device RegistrationResearch ReportContinuous Glucose Monitors: The Global Regulatory MapResearch ReportAI as a Medical Device: The Global Regulatory MapBlog ArticleTurn FDA & EU Approvals Into Global Market AccessBlog ArticleWireless Compliance for Medical Device Manufacturers: Overview of Radio Frequency Module IntegrationVideoHow to Register a Medical Device with the US FDAMarket ServiceFDA 483 and Warning Letter Response and ConsultingMarket ServiceFDA Certificate to Foreign Government (CFG) for Medical DevicesVideoUnderstanding Mexico's New Abbreviated PathwayVideoBrazil’s UDI: Key Insights for Medical Device ManufacturersLet's Talk,
Anywhere You Are.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Contact us